Home > Boards > US Listed > Biotechs >

CureVac B.V. (CVAC)

Add CVAC Price Alert      Hide Sticky   Hide Intro
Moderator: mick
Search This Board: 
Last Post: 7/10/2021 10:52:34 PM - Followers: 10 - Board type: Free - Posts Today: 0


prophylactic vaccines

See where we’re heading









Lassa, yellow fever



Respirational syncytial virus


Other infectious diseases



Various projects


Rota, malaria, universal influenza



cancer immunotherapies


HUGE DROP IN SHARES 06-16-2021 A.H. OVER $50
About 11 mil. left for trading 3-1/2 % are shorted What Type Of Shareholders Own The Most Number of CureVac N.V. (NASDAQ:CVAC) Shares?
Simply Wall St
Wed, June 9, 2021, 11:47 PM·4 min read

always like to check for a history of revenue growth. You can too, by accessing this free chart of historic revenue and earnings in this detailed graph.

If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.


Insider Own 55.92%
Inst Own 23.40%
Shs Outstand 177.97M
Shs Float 82.25M
Short Float 3.59%
The big shareholder groups in CureVac N.V. (NASDAQ:CVAC) have power over the company. Large companies usually have institutions as shareholders,
and we usually see insiders owning shares in smaller companies.
Warren Buffett said that he likes "a business with enduring competitive advantages that is run by able and owner-oriented people."
So it's nice to see some insider ownership, because it may suggest that management is owner-oriented.
With a market capitalization of US$21b, CureVac is rather large. We'd expect to see institutional investors on the register.
Companies of this size are usually well known to retail investors, too.
Taking a look at our data on the ownership groups (below), it seems that institutions are noticeable on the share registry.
Let's delve deeper into each type of owner, to discover more about CureVac.
View our latest analysis for CureVac
What Does The Institutional Ownership Tell Us About CureVac?
Institutional investors commonly compare their own returns to the returns of a commonly followed index.
So they generally do consider buying larger companies that are included in the relevant benchmark index.
As you can see, institutional investors have a fair amount of stake in CureVac.
This can indicate that the company has a certain degree of credibility in the investment community.
However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes.
When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'.
When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth.
You can see CureVac's historic earnings and revenue below, but keep in mind there's always more to the story.
CureVac is not owned by hedge funds. Looking at our data, we can see that the largest shareholder is dievini Hopp BioTech holding GmbH & Co. KG with 42% of shares outstanding.
KfW, Asset Management Arm is the second largest shareholder owning 16% of common stock, and GlaxoSmithKline plc holds about 8.0% of the company stock.
Story continues
A more detailed study of the shareholder registry showed us that 2 of the top shareholders have a considerable amount of ownership in the company, via their 58% stake.

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments.
There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

Insider Ownership Of CureVac

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least.
Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company.
However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

We can see that insiders own shares in CureVac N.V.. It is a very large company, and board members collectively own US$1.1b worth of shares (at current prices).
It is good to see this level of investment. You can check here to see if those insiders have been buying recently.

General Public Ownership

With a 21% ownership, the general public have some degree of sway over CureVac. While this group can't necessarily call the shots,
it can certainly have a real influence on how the company is run.

Arcturus Therapeutics

CureVac has entered into a collaboration with Arcturus Therapeutics Ltd. (NASDAQ:ARCT), an RNA medicines company,
to access the full suite of Arcturus’ lipid-mediated delivery intellectual property to enable the development of mRNA product candidates.



CureVac Announces Pricing of Initial Public Offering

"" rel="nofollow ugc" target="_blank">https://www.curevac.com/news/curevac-announces-pricing-of-initial-public-offering"; style="box-sizing: border-box; -webkit-tap-highlight-color: transparent; outline: 0px; color: rgb(241, 110, 48); text-decoration-line: none; background-color: transparent; font-family: "Open Sans", sans-serif; font-weight: 600; margin-right: 20px; line-height: 22px;" target="_blank" rel="nofollow ugc"> Email Press Release  PDF version 

TÜBINGEN, Germany/ BOSTON, USA – August 14, 2020 – CureVac B.V. (“CureVac” or the “Company”), a clinical-stage biopharmaceutical company
developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today the pricing of its
initial public offering of 13,333,333 common shares at an initial public offering price of $16.00 per common share, for total gross proceeds of approximately $213.3 million.
In addition, the Company has granted the underwriters a 30-day option to purchase up to an
additional 1,999,999 common shares at the public offering price, less underwriting discounts and commissions. All of the common shares are being offered by CureVac.
The shares are scheduled to begin trading on the Nasdaq Global Market today, August 14, 2020, under the ticker symbol “CVAC.”
The offering is expected to close on August 18, 2020, subject to customary closing conditions.

BofA Securities, Jefferies and Credit Suisse are acting as joint book-running managers for the proposed offering, with Berenberg and Kempen & Co acting as passive book-running managers.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission (“SEC”) on August 13, 2020.
The offering is being made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained, when available,
for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, copies of the final prospectus, when available, may be obtained from
BofA Securities, Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001,
by telephone at (800) 299-1322 or by email at dg.prospectus_requests@bofa.com; Jefferies LLC, Attention:
Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com;
and Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, North Carolina 27560, by telephone at (800) 221-1037 or by email at usa.prospectus@credit-suisse.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities,
nor shall there be any sale of these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About CureVac
CureVac is a global clinical-stage biopharmaceutical company in the field of messenger RNA (mRNA) technology with expertise in developing
and optimizing this versatile molecule for medical purposes.
The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases.
The company applies its technologies for the development of prophylactic vaccines, cancer therapies,
antibody therapies and the treatment of protein therapies. CureVac is headquartered in Tübingen, Germany with sites in Frankfurt and Boston, USA.

CureVac Investor Relation Contact
Dr. Sarah Fakih, Vice President Investor Relations
CureVac, Tübingen, Germany
T: +49 7071 9883-1298
M: +49 160 90 496949

CureVac Media Contact
Thorsten Schüller, Director Corporate Communications
CureVac, Tübingen, Germany
T: +49 7071 9883-1577

 *DISCLAIMER *The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.


Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVAC News: CureVac plans to move forward with COVID vaccine despite data; shares down 13% 07/01/2021 08:13:43 AM
CVAC News: CureVac shares drop 9% on final data from phase 2b/3 trial on COVID vaccine 06/30/2021 05:03:57 PM
CVAC News: Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) 06/30/2021 04:35:25 PM
CVAC News: Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) 06/29/2021 07:05:47 AM
CVAC News: Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) 06/24/2021 04:17:17 PM
#106  Sticky Note About 11 mil. left for trading 3-1/2 % mick 06/16/21 07:48:04 PM
#115   CureVac NV (CVAC) mick 07/10/21 10:52:34 PM
#114   i got some @ $43 'CureVac B.V. (CVAC)' mick 06/19/21 07:04:26 PM
#113   CVAC-this was a good falling knife trade ;) Nebuchadnezzar 06/19/21 12:31:28 PM
#112   great thank you for sharing i did more mick 06/16/21 08:32:41 PM
#111   I'm lucky I got in early in October Go Hawks13 06/16/21 08:27:19 PM
#110   $CVAC [-chart]www.curevac.com/wp-content/uploads/2020/06/curevac-logo-claim-gray-fin.svg mick 06/16/21 08:10:25 PM
#109   $CVAC also has big , huge pipeline too. mick 06/16/21 08:06:57 PM
#108   i decided to also. i bought near closing mick 06/16/21 07:57:54 PM
#107   I was working and didn't even see the Go Hawks13 06/16/21 07:54:33 PM
#106   About 11 mil. left for trading 3-1/2 % mick 06/16/21 07:48:04 PM
#105   Bad Efficacy news hit for their MRNA Covid Vaccine. smitter 06/16/21 07:42:19 PM
#104   only 2.66 mil traded & dumped to under mick 06/16/21 07:39:47 PM
#103   i bought da dipper $44 CureVac NV (CVAC) mick 06/16/21 07:37:09 PM
#102   CureVac NV (CVAC) mick 06/16/21 07:36:03 PM
#101   $CVAC interesting day, closed @ 90 plus but mick 06/16/21 07:35:52 PM
#100   Well that didn't go well. I should have Go Hawks13 06/16/21 07:29:54 PM
#99   CVAC ouch Nebuchadnezzar 06/16/21 05:14:48 PM
#98   Covid MRNA Falls short in trials. CVAC. Would smitter 06/16/21 04:44:35 PM
#97   CureVac NV (CVAC) mick 05/26/21 12:05:49 PM
#96   www.stockscores.com/chart.asp?TickerSymbol=CVAC&TimeRange=180&Interval=d& mick 05/02/21 07:39:41 PM
#95   Pfizer,s Ceo says that it will take a Eaglepointone 04/29/21 08:30:13 AM
#94   127$/SHARE Eaglepointone 04/28/21 08:11:07 AM
#93   124$/share Eaglepointone 04/27/21 09:30:41 AM
#92   https://www.usnews.com/news/world/articles/2021-04-27/novartis-ceo-says-could-bo Eaglepointone 04/27/21 06:14:47 AM
#91   120$/share Curevac is close to getting approval for its Eaglepointone 04/27/21 02:53:00 AM
#90   A new blow to the supply of vaccines, Eaglepointone 04/26/21 07:43:05 AM
#89   We will need a third booster shot for Eaglepointone 04/23/21 05:36:37 AM
#88   114$/share Eaglepointone 04/23/21 05:09:14 AM
#87   "Swiss drugmaker Novartis has agreed to help make Eaglepointone 04/21/21 08:12:09 AM
#86   "Expanded manufacturing network with European partners expected to Eaglepointone 04/21/21 08:04:17 AM
#85   CureVac NV (CVAC) mick 04/18/21 01:53:43 PM
#84   104 $/share Eaglepointone 04/15/21 03:32:36 PM
#83   Demand for effective vaccines increases in Europe and Eaglepointone 04/13/21 08:02:28 AM
#82   https://finance.yahoo.com/news/curevac-says-may-approval-covid-080402264.html?gu Eaglepointone 04/12/21 09:24:06 AM
#81   https://www.cnbc.com/2021/04/08/covid-vaccine-maker-curevac-hopes-shot-will-get- Eaglepointone 04/08/21 07:22:59 PM
#80   "CureVac reaffirms an expected output capacity of its Eaglepointone 04/08/21 07:16:43 PM
#79   Great demand for vaccines in Europe and in Eaglepointone 04/01/21 05:09:27 AM
#77   CureVac NV (CVAC) mick 02/20/21 06:49:45 PM
#76   CureVac NV (CVAC) mick 02/20/21 06:49:45 PM
#75   https://otcbb.swingtradebot.com/equities/CVAC N.Y. , NASDAQ mick 01/31/21 04:17:19 PM
#74   https://pennystocks.news/otc/?symbol=CVAC mick 01/03/21 12:22:54 PM
#73   WOW CVAC OUTSTANDING mick 01/03/21 12:22:42 PM
#72   Can’t believe I bought this at 67 and NYCPuglet 12/11/20 08:41:44 PM
#71   CureVac NV (CVAC) mick 12/07/20 01:13:26 PM
#70   CureVac's bigger story mick 11/27/20 11:56:42 AM
#69   CureVac NV (CVAC) mick 11/17/20 01:32:21 PM
#68   $CVAC Fauci says Covid-19 vaccine may not get SpotOnTrade 10/28/20 09:58:31 PM
#67   CureVac NV (CVAC) mick 10/25/20 05:06:07 PM
#66   mRNA is Trending as other Age Groups become Nfixus 10/14/20 03:29:30 PM
#65   ... UH DUH $CVAC IS A BUY ... @LaughinPaulRyan 09/29/20 04:39:43 PM
Consent Preferences